| 08.00 - 10.30 | Session 6: New treatment modalities in kidney cancer |  | |
| 08.00 - 08.45 |
Case discussions: Minimally-invasive approaches to small renal tumours | ||
| Moderators: |
J. De La Rosette, Amsterdam (NL) J. Knox, Toronto (CA) |
||
| Panel: |
A. Alcaraz, Barcelona (ES) D. Jacqmin, Strasbourg (FR) M. Remzi, Vienna (AT) |
||
| 08.45 - 09.00 |
State-of-the-art lecture: Are active surveillance strategies viable options in the treatment of renal cell cancer? M. Stöckle, Homburg (DE) |
| |
| 09.00 - 09.15 |
State-of-the-art lecture: Do costs and benefits justify the use of new targeted agents in metastatic RCC? P. Nathan, Northwood (GB) |
| |
| 09.15 - 09.30 |
State-of-the-art lecture: Sequential and intermittent systemic treatment in RCC J. Knox, Toronto (CA) |
| |
| 09.30 - 10.00 | Coffee Break and Poster Viewing | ||
| 10.00 - 10.15 |
State-of-the-art lecture: Is nephrectomy in metastatic renal cell cancer necessary in the era of targeted therapy? D. Jacqmin, Strasbourg (FR) |
| |
| 10.15 - 10.30 |
State-of-the-art lecture: The role of neoadjuvant and adjuvant therapy in metastatic RCC P. Mulders, Nijmegen (NL) |
| |
| 10.30 - 12.00 |
Session 7: Meet the experts Case discussions on renal cell cancer | ||
| Moderators: |
P. Hoskin, Northwood (GB) D. Jacqmin, Strasbourg (FR) P. Nathan, Northwood (GB) |
||
| Panel: |
B. Escudier, Villejuif (FR) J. Knox, Toronto (CA) P. Mulders, Nijmegen (NL) S. Osanto, Leiden (NL) M. Remzi, Vienna (AT) |
||
| 12.00 - 13.30 | Lunch Break and Poster Viewing | ||
| 13.30 - 15.00 | Session 8: Poster presentations on prostate, bladder and kidney cancer | ||
| Chairs: | F. Debruyne, Nijmegen (NL) B. Escudier, Villejuif (FR) V. Khoo, London (GB) |
||
| P001 Hypofractionation vs. conventional fractionation radiotherapy in patients with high risk prostate cancer: Early results of a phase III randomised study |  | ||
| Saracino B., Arcangeli S., Gomellini S., Petrongari M.G., Sentinelli S., Fowler J., Strigari L., Arcangeli G. (Rome, Italy; Madison, United States of America) | |||
| P002 Histone deacetylase inhibitor belinostat (pxd-101) represses androgen receptor expression and acts synergistically with castration and bicalutamide treatment to inhibit prostate cancer growth in hormone refractory models | | ||
| Festuccia C., Gravina G.L., Muzi P., Ricevuto E., D’Ascenzo S., Dolo V., Ficorella C. (L'aquila, Italy) | |||
| P003 The first set of nomograms predicting late rectal toxicity in prostate cancer patients undergoing 3DCRT: Development and internal validation | | ||
| Valdagni R., Kattan M.W., Rancati T., Yu C., Vavassori V., Fellin G., Bianchi C., Menegotti L., Monti A., Stasi M., Baccolini M., Fiorino C. (Milan, Varese, Trento, Como, Torino, Lugo, Italy; Cleveland, United States of America) | |||
| P004 Long-term safety and tolerability of abiraterone acetate (AA) in advanced castration resistant prostate cancer (CRPC) | | ||
| Bianchini D., Zivi A., Sandu S., Attard G., Read A., Molife R., Fong P., Olmos D., Oomen N.B., Massard C., Hunt J., Thompson E., Parker C., Dearnaley D., De Bono J.S. (Sutton, United Kingdom) | |||
| P005 Molecular genetic alterations and their predictive values in superficial bladder cancer | | ||
| Babayan A., Bashkatov S., Karyakin O., Teplov A., Golovashenko M., Zaletaev D., Nemtsova M. (Moscow, Obninsk, Russia) | |||
| P006 Paclitaxel plus hyaluronic acid for intravesical therapy of carcinoma in situ of the bladder refractory BCG treatment: Preliminary results of a phase I study | | ||
| Bassi P.F., Volpe A., D'agostino D., Cappa E., Sacco E., Miglioranza E., Racioppi M. (Rome, Italy) | |||
| P007 Micropapillary urothelial carcinoma of the urinary bladder: Early radical surgery or neoadjuvant chemotherapy? | | ||
| Ghoneim I.A., Stephenson A.J., Gong M.C., Campbell S.C., Hansel D., Fergany A.F. (Cleveland, Ohio, United States of America) | |||
| P008 A randomised prospective phase II study with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first-line treatment in advanced renal cell cancer (RCC): ROSORC trial | | ||
| Procopio G., Verzoni E., Bracarda S., Cascinu S., Manzoni M., Salvioni R., Bregni M., Celio L., Ortega C., Bajetta E. (Milano, Perugia, Ancona, Candiolo, Italy) | |||
| P009 Accelerated growth of renal carcinoma cells after radiofrequency ablation | | ||
| Kroeze S.G.C., Kruijssen L.J.W., Van Diest P.J., Bosch J.L.H.R., Jans J.J.M. (Utrecht, The Netherlands) | |||
| P010 Assessment of quality of life (QOL) in treatment-naïve and cytokinepretreated patients with advanced renal cell carcinoma (RCC) treated with pazopanib in a phase III double-blind, placebo-controlled trial | | ||
| Hawkins R., Hodge R., Chen M., Neary M.P., Pickard A.S., Sternberg C., Ralph, C. (Manchester, Uxbridge, United Kingdom; Collegeville, Chicago, United States of America; Rome, Italy) | |||
| 15.00 - 15.30 | Coffee Break and Poster Viewing | ||
| 15.30 - 17.00 | Session 9: What is new in prostate cancer? | ||
| Round table session - An update of new technologies and treatment modalities in prostate cancer (with use of audience response system) | |||
| Moderators: | P-A. Abrahamsson, Malmö (SE) J. Bellmunt, Barcelona (ES) | ||
| Panel: | A. Alcaraz, Barcelona (ES) J. De Bono, Sutton (GB) J. De La Rosette, Amsterdam (NL) G. De Meerleer, Ghent (BE) A. Zietman, Boston (US) | | |
 |
 |
 |
 |